Adult Solid Tumor Clinical Trial
Official title:
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors. In this study, a 3 + 3 dose escalation design was used. The patients will be given different doses(500mg, 800mg Q3W) of HLX26 Plus fixed dose of HLX10(300mg) intravenously. Observation period of DLT lasts for 3 weeks after the first administration of HLX26. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04538625 -
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
|
Phase 3 | |
| Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
| Recruiting |
NCT06403436 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03061305 -
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
|
||
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Terminated |
NCT05357898 -
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06277804 -
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
|
Phase 1 | |
| Completed |
NCT03818347 -
Hydrogen Gas for Cancer Rehabilitation
|
N/A | |
| Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
| Completed |
NCT01269918 -
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
|
N/A | |
| Suspended |
NCT03253575 -
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
|
||
| Completed |
NCT04084951 -
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03760952 -
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
|
||
| Active, not recruiting |
NCT03445858 -
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
|
Early Phase 1 | |
| Completed |
NCT03303365 -
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
|
N/A | |
| Not yet recruiting |
NCT05666635 -
Study of LTC004 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT05147272 -
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04892043 -
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1 |